Early onset of reduction in relapses with Rebif® vs placebo1
The primary IMPROVE endpoint was the number of combined unique active lesions at week 16: 0.9 (SD 1.4) for Rebif® 44μg three times a week subcutaneously (SC tiw) vs 3.0 (SD 4.1) for placebo (P<0.001)6
As early as month 4, patients with active relapsing-remitting multiple sclerosis (RRMS) showed a significant reduction in relapse rate with Rebif® 44μg (SC tiw) vs placebo (P=0.010)*1
Rebif® was effective at keeping patients relapse-free vs placebo2
Twice as many patients were relapse-free with Rebif® at 2 years, compared with placebo (P<0.005).2†
Rebif® significantly reduced relapse rate at 24 weeks vs IFNβ-1a IM5
Patients treated with Rebif® were significantly more likely to be relapse-free at 24 weeks than those treated with IFN β-1a IM (odds ratio 1.9, 95% CI 1.3–2.6; P=0.0005).